肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

JCI：胡国宏等DLC1调控乳腺癌细胞骨转移研究获进展

2014-03-26 上海生命科学研究院 上海生命科学研究院

DLC1乳腺癌
关注

3月3日，国际学术期刊The Journal of Clinical Investigation 在线发表了中国科学院上海生命科学研究院健康科学研究所胡国宏研究组与山东大学齐鲁医院杨其峰研究组合作完成的题为DLC1-dependent parathyroid hormone - like hormone inhibition suppresses breast cancer bone metast

3月3日，国际学术期刊The Journal of Clinical Investigation 在线发表了中国科学院上海生命科学研究院健康科学研究所胡国宏研究组与山东大学齐鲁医院杨其峰研究组合作完成的题为DLC1-dependent parathyroid hormone - like hormone inhibition suppresses breast cancer bone metastasis 的最新研究成果。论文首次报道了DLC1（deleted in liver cancer 1）通过抑制SMAD3 连接区域的磷酸化，降低TGFβ诱导的PTHLH 表达水平，最终阻碍乳腺癌的骨转移进程。

乳腺癌是对女性健康构成很大威胁的一种恶性疾病。而乳腺癌向重要器官如骨、肺、脑、肝等的转移是乳腺癌致死的主要原因。临床上的数据显示大约70%的晚期乳腺癌病人会发生骨转移。乳腺癌发生骨转移可能会给病人带来疼痛、骨折和高钙血等症状，这使得病人生活质量非常之低。以前的研究表明在乳腺癌骨转移过程中破骨细胞发挥着关键性的作用，临床上用于治疗乳腺癌骨转移的两类药物Bisphosphonates和RANKL抗体（比如Denosumab）主要机制即是抑制破骨细胞活性，具体而言，前者能引发破骨细胞发生细胞凋亡，后者通过竞争性结合RANKL而阻碍破骨细胞的成熟。两种药物能在一定程度上缓解病人的症状但对患者的生存率影响不大，因此开发出更有效地阻止乳腺癌骨转移的药物迫在眉睫。

上海生科院健康所博士研究生王宇峰等在胡国宏研究员的指导下，与齐鲁医院合作，利用具有不同骨转移能力的乳腺癌细胞亚系作为模型，结合小动物活体成像的检测发现DLC1在乳腺癌骨转移过程中起着关键性的负调控作用。他们的研究证明，DLC1功能的行使依赖于它失活RHO-ROCK通路，继而抑制TGFβ诱导的SMAD3 linker region磷酸化。DLC1对后者的抑制降低了TGFβ诱导的PTHLH 的转录和分泌，从而减少骨转移微环境中的成熟破骨细胞，最终阻碍了乳腺癌的破骨性转移。同时他们用一种已通过FDA审批的ROCK抑制剂Fasudil治疗乳腺癌骨转移，结果显示Fasudil能有效阻遏骨转移的进程，这暗示这种药物或许具有进行临床试验的价值。该研究首次证明DLC1-RHO信号通路在调控乳腺癌骨转移微环境中的重要作用，也为临床上治疗乳腺癌骨转移提供了新思路。

该项工作获得国家科技部“973”项目、国家自然科学基金委及中国科学院项目的经费资助。

原始出处

Wang Y, Lei R, Zhuang X, Zhang N, Pan H, Li G, Hu J, Pan X, Tao Q, Fu D, Xiao J, Chin YE, Kang Y, Yang Q, Hu G.DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis.J Clin Invest. 2014 Mar 3

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1981977, encodeId=c04819819e703, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Jun 22 18:37:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801213, encodeId=20ad180121303, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Feb 20 20:37:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985340, encodeId=73cb1985340ec, content=<a href='/topic/show?id=e489603061' target=_blank style='color:#2F92EE;'>#DLC1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6030, encryptionId=e489603061, topicName=DLC1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Fri May 02 07:37:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251974, encodeId=1d7012519e419, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Mar 28 00:37:00 CST 2014, time=2014-03-28, status=1, ipAttribution=)]
    2014-06-22 caobinglei8079

    #JCI#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1981977, encodeId=c04819819e703, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Jun 22 18:37:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801213, encodeId=20ad180121303, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Feb 20 20:37:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985340, encodeId=73cb1985340ec, content=<a href='/topic/show?id=e489603061' target=_blank style='color:#2F92EE;'>#DLC1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6030, encryptionId=e489603061, topicName=DLC1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Fri May 02 07:37:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251974, encodeId=1d7012519e419, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Mar 28 00:37:00 CST 2014, time=2014-03-28, status=1, ipAttribution=)]
    2015-02-20 axin009

    #研究获进展#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1981977, encodeId=c04819819e703, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Jun 22 18:37:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801213, encodeId=20ad180121303, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Feb 20 20:37:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985340, encodeId=73cb1985340ec, content=<a href='/topic/show?id=e489603061' target=_blank style='color:#2F92EE;'>#DLC1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6030, encryptionId=e489603061, topicName=DLC1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Fri May 02 07:37:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251974, encodeId=1d7012519e419, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Mar 28 00:37:00 CST 2014, time=2014-03-28, status=1, ipAttribution=)]
    2014-05-02 12498b37m72暂无昵称

    #DLC1#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1981977, encodeId=c04819819e703, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Jun 22 18:37:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801213, encodeId=20ad180121303, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Feb 20 20:37:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985340, encodeId=73cb1985340ec, content=<a href='/topic/show?id=e489603061' target=_blank style='color:#2F92EE;'>#DLC1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6030, encryptionId=e489603061, topicName=DLC1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Fri May 02 07:37:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251974, encodeId=1d7012519e419, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Mar 28 00:37:00 CST 2014, time=2014-03-28, status=1, ipAttribution=)]
    2014-03-28 yxch36

    #癌细胞#

    0